Ubs Asset Management Americas Inc Day One Biopharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 69,730 shares of DAWN stock, worth $983,193. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,730
Previous 37,879
84.09%
Holding current value
$983,193
Previous $625,000
53.6%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DAWN
# of Institutions
165Shares Held
71.7MCall Options Held
163KPut Options Held
183K-
Ra Capital Management, L.P. Boston, MA7.87MShares$111 Million1.63% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$90.7 Million11.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$65.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$63.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.78MShares$53.3 Million0.02% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.04B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...